Good but not good enough: Clinical trial participation of patients with myelodysplastic syndromes
|
Aug 2020
|
Cancer
|
myelodysplastic syndromes (MDS)
|
Hypomethylating agents in combination with histone deacetylase inhibitors in higher risk myelodysplastic syndromes: Is there a light at the end of the tunnel?
|
Jan 2017
|
Cancer
|
myelodysplastic syndromes (MDS)
|
Phase 2, randomized, double-blind study of pracinostat in combination with azacitidine in patients with untreated, higher risk myelodysplastic syndromes
|
Jan 2017
|
Cancer
|
myelodysplastic syndromes (MDS)
|
Lenalidomide performance in the real world: Patterns of use and effectiveness in a Medicare population with myelodysplastic syndromes.
|
Aug 2013
|
Cancer
|
myelodysplastic syndromes (MDS)
|
Counselling and adverse event management for patients with myelodysplastic syndromes undergoing azacitidine therapy: a practice standard for Canadian nurses
|
Oct 2012
|
Can Oncol Nurs J
|
myelodysplastic syndromes (MDS)
|
Therapy-related myelodysplastic syndromes in the genomics era
|
Jun 2023
|
Bulletin du Cancer
|
myelodysplastic syndromes (MDS)
|
The evolving role of next generation sequencing in myelodysplastic syndromes
|
Oct 2019
|
British Journal of Haematology
|
myelodysplastic syndromes (MDS)
|
PNH Phenotypes and Their Genesis
|
Jun 2020
|
British Journal of Haematology
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
Paroxysmal nocturnal haemoglobinuria (PNH): novel therapies for an ancient disease
|
Nov 2020
|
British Journal of Haematology
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
In Search for a Haemoglobin Threshold in Myelodysplastic Syndromes
|
Jun 2020
|
British Journal of Haematology
|
myelodysplastic syndromes (MDS)
|